ClinicalTrials.gg
CompletedNCT07345442Updated Jan 15, 2026

Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects

A Phase 1 interventional study of PA9159 nasal spray solution, 80 μg one day treatment and PA9159 nasal spray solution, 160 μg one day treatment in Allergic Rhinitis, sponsored by Anhui Palo Alto Pharmaceuticals, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Anhui Palo Alto Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 82 studies in Rhinitis, Allergic with a site in China — 32 open to participants now, 34 under way, 2 of them phase 3. Rhinitis, Allergic · China.

Enrollment
59th of 67
36 · median 93
Started
2025
with 9 others
Phase 1
8 of 82
1 open now
Registered
73rd of 82
by date
Lead sponsor
3 of 82
Anhui Palo Alto Pharmaceuticals, Inc.

Among the 82 studies in Rhinitis, Allergic with a site in China, this one is the 59th largest by enrollment of the 67 interventional ones that give a count, is one of 10 that started in 2025, is one of 8 in phase 1, and was the 73rd registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

32 of the 82 studies in Rhinitis, Allergic with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Rhinitis, Allergic with a site in China, or all of them as a file.
02

Study summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of intranasal PA9159, to establish maximum tolerated dose in healthy chinese adult

Read the detailed description

This is a randomized, double-blind, placebo-controlled dose escalation phase 1 trial, including single dose and 7-day repeat doses of PA9159 nasal spray. In the study, the treatment is given once for one day, with escalation doses of 80 μg, 160 μg, 320 μg. After two days elution, PA9159 at the escalation dose of 80 μg, 160 μg, 320 μg is given once a day for 7 days. 12 health subjects will be enrolled for each dose group, randomized proportionally at 3:1 ratio to receive either the investigational product PA9159 or placebo nasal spray, with a total of 36 subjects for this two-part study. Subjects will be evaluated for the safety, tolerability and pharmacokinetics of PA9159 intranasal spray.

03

Conditions studied

  • Allergic Rhinitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18 to 65 years (including upper and lower limits);
  • Male body weight ≥ 50 kg, female weight ≥ 45 kg, (BMI) between 19 and 26 kg/m2 (including cut-off values);
  • Voluntary participation and signing of .

Exclusion criteria

Exclusion Criteria:

  • Those who cannot properly use a nasal spray, cannot tolerate nasal administration, or fail nasal spray administration training;
  • Those with special dietary requirements who cannot adhere to a standard diet;
  • Those with a history of serious diseases affecting the respiratory, cardiovascular, digestive, endocrine, hematologic, immune, or nervous systems, or currently suffering from diseases of the aforementioned systems;
  • A history of recurrent (defined as more than once) or disseminated shingles, glaucoma, cataracts, or ocular infectious diseases;
  • Allergic to the drug or any component of the investigational drug, or having an allergic constitution (referring to being allergic to two or more foods, drugs, or environmental substances);
  • Vital signs during the screening period, physical examination, nasal examination, laboratory tests (complete blood count, blood biochemistry, urinalysis, coagulation function), serum cortisol, chest X-ray, abdominal ultrasound, 12-lead , and other abnormalities judged by the investigator to be ;
  • Those who test positive for surface antigen (HBsAg), virus antibody (HCV Ab), syphilis treponemal antibody (Syphilis TP), or (HIV Ag/Ab);
  • Exclude individuals who have frequently consumed alcohol in the past three months, defined as drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol, 45 mL of spirits with 40% alcohol, or 150 mL of wine with 12% alcohol), or those who tested positive on baseline breath alcohol tests, or those unable to stop alcohol intake during the study period;
  • Those with a smoking history of more than 10 years, or who smoke more than 5 cigarettes per day in the 3 months prior to screening, or who cannot stop using any tobacco products during the trial, or who test positive for nicotine at baseline;
  • Individuals with a history of drug abuse or drug use in the past two years, or those who tested positive for drug use in baseline urine screening;
  • Individuals who have taken any medication (prescription drugs, over-the-counter drugs, Chinese herbal medicine, vaccines) or health supplements within the 2 weeks prior to screening or during the screening period;
  • Exclude individuals who have used preparations containing or any drugs affecting enzyme activity within the 30 days prior to screening or during the screening period;
  • Participants who have consumed beverages or foods containing grapefruit, dragon fruit, mango, pomelo, pomegranate, papaya, or star fruit within 14 days prior to screening and during the screening period, or who do not agree to stop consuming the above foods during the trial;
  • Anyone who consumes any foods or beverages rich in caffeine or methylxanthines (such as coffee, tea, cola, chocolate, seafood, cocoa, animal liver, etc.) within 48 hours prior to the first use of the investigational drug, or who does not agree to stop consuming the above foods during the trial;
  • Individuals who have donated blood or experienced significant blood loss (≥400 mL) within the 90 days prior to screening, or who have used blood products or received a transfusion;
  • Participants who have taken part in other clinical studies and used study products within the 90 days prior to screening;
  • Individuals who have previously undergone respiratory system surgery, have had major surgery within the three months prior to screening (as determined by the investigator based on past medical history), have experienced major trauma, or plan to undergo surgery during the study period;
  • Difficulty with venous blood collection, or a known history of fainting at the sight of needles or blood;
  • Women who test positive for pregnancy or are breastfeeding;
  • Researchers believe there are other situations in which participation in the trial is not suitable, or the subject cannot participate in the trial due to personal reasons.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    PA9159 80 μg single dose and placebo

    Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either single dose of 80 μg PA9159 or placebo. There will be a follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.

    Drug: PA9159 nasal spray solution, 80 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 160 μg single dose and placebo

    Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either single dose of 160 μg PA9159 or placebo. There will be a follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.

    Drug: PA9159 nasal spray solution, 160 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 320 μg single dose and placebo

    Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either single dose of 320 μg PA9159 or placebo. There will be a follow-up period to review all available clinical and laboratory safety data.

    Drug: PA9159 nasal spray solution, 320 μg one day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 80 μg repeated doses and placebo

    Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 80 μg PA9159 or placebo once a day for 7 days. There will be follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.

    Drug: PA9159 nasal spray solution, 80 μg 7-day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 160 μg repeated doses and placebo

    Twelve Ten subjects will be randomly assigned at a 3: 1 ratio to receive either 160 μg PA9159 or placebo once a day for 7 days. There will be follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.

    Drug: PA9159 nasal spray solution, 160 μg 7-day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

  • Experimental
    PA9159 320 μg repeated doses and placebo

    Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 320 μg PA9159 or placebo once a day for 7 days. There will be a follow-up period to review all available clinical and laboratory safety data.

    Drug: PA9159 nasal spray solution, 320 μg 7-day treatment · Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects experiencing adverse events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which does not necessarily have a causal relationship with this treatment.

    Time frame: up to 7 days after last nasal spray treatment

Secondary outcomes

  1. Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-Cmax

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Maximum Observed Plasma Concentration (Cmax)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 0.5, 1, 1, 2, 4, 6, 8, 12,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

  2. Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-Tmax

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 0.5, 1, 1, 2, 4, 6, 8, 12,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

  3. Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-AUC

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Area Under the Plasma Concentration-Time Curve (AUC)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 0.5, 1, 1, 2, 4, 6, 8, 12,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

  4. Pharmacokinetics of single dose and repeat doses of Nasal Spray PA9159-T1/2

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Elimination Half-Life Period (T1/2)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects) 0.5, 1, 1, 2, 4, 6, 8, 12,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

07

Study locations

1 site
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jun 2025, 2 months.

Of 25 phase 1 interventional studies under Rhinitis, Allergic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 15, 2026
StartActual
Mar 14, 2025
Primary completionActual
Jun 9, 2025
CompletionActual
Jun 9, 2025
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07345442
Lead sponsor
Anhui Palo Alto Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Mar 14, 2025
Primary completion
Jun 9, 2025
Completion
Jun 9, 2025
Last update
Jan 15, 2026

Study contacts

Jinhua Wen
principal investigator · The First Affiliated Hospital of Nanchang University
Xiaohua Cheng
principal investigator · The First Affiliated Hospital of Nanchang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA9159

Start the discussion